ライフサイエンスコーパス: BDA

1 BDA and Cl-BDA formation was also observed during the ch

2 BDA did not label the nearby C1 cells.

3 BDA injection in the lateral part of the lateral parafas

4 BDA injection in the medial parafascicular nucleus and t

5 BDA injection in the medial part of the lateral parafasc

6 BDA positive cases showed a marked accumulation of poor

7 BDA Sanger method also enabled detection and quantitatio

8 BDA Sanger, ddPCR, and NGS (with orthogonal confirmation

9 BDA was iontophoresed unilaterally into the caudal Vme,

10 BDA-366 suppresses growth of lung cancer xenografts deri

11 BDA-366-Bcl2 binding induces conformational change in Bc

12 BDA-ir varicosities were found in the solitary tract nuc

13 BDA-labeled fibers from the SCN and vSPVZ formed apposit

14 BDA-labeled projection neurons varied widely in the shap

15 BDA-labeled terminals often apposed MOR-immunoreactive d

16 BDA-labeled terminals were closely apposed upon HRP retr

17 A total of 1408 BDA-labeled boutons were examined ultrastructurally, whi

18 Of the 1408 BDA-labeled boutons, 69.6% of them were S-type boutons c

19 exhibited at least one close contact with a BDA-labeled vagal bouton, although most of these cells r

20 ayered Dion-Jacobson type with m = 2 and A = BDA, M(I) = Ag, M(III)= In or Bi, X = Cl or Br) and PA(2

21 Using a Bax degradation activity (BDA) assay, CLL cells were found to show variable Bax in

22 osome (Chr) 4 for the renal traits, adjusted BDA, and cholangitis with logarithm of odds scores of 18

23 r the left parietal cortex immediately after BDA injections.

24 for MOR were seen in 14% (134 of 938) of all BDA-labeled axons and axon terminals.

25 of a mixture of biotinylated dextran amine (BDA) and (3)H-leucine was made into the marginal shell o

26 present study employed biotin dextran amine (BDA) and cholera toxin B subunit (CTB) as anterograde an

27 e group of rats, biotinylated dextran amine (BDA) and Fluoro-Ruby (FR) were injected into separate ba

28 erograde tracers biotinylated dextran amine (BDA) and fluoro-ruby (FR) were injected into separate pa

29 erograde tracers biotinylated dextran amine (BDA) and fluoro-ruby (FR) were injected into the whisker

30 erograde tracers biotinylated dextran amine (BDA) and fluororuby (FR) were injected into the whisker

31 al labeling with biotinylated dextran amine (BDA) and identifying patch and matrix in the same sectio

32 rograde tracers, biotinylated dextran amine (BDA) and Phaseolus vulgaris-leucoagglutinin (PHA-L), int

33 tudied using the biotinylated dextran amine (BDA) anterograde tracing method in the rat.

34 c tracers such a biotinylated dextran amine (BDA) are used to label regenerating fibers after therape

35 ll injections of biotinylated dextran amine (BDA) as an anterograde tracer in various parts of the DS

36 By using biotinylated dextran amine (BDA) as anterograde tracer, we characterized the topogra

37 ade transport of biotinylated dextran amine (BDA) following injections into the rat prefrontal cortex

38 hus, we injected biotinylated dextran amine (BDA) in CRNs to study their projections with light and e

39 terograde tracer biotinylated dextran amine (BDA) in lactating rats and DIO mice.

40 etic deposits of biotinylated dextran amine (BDA) in the area of the rVRG, many BDA-labeled terminals

41 ns of the tracer biotinylated dextran amine (BDA) in the dorsal lateral geniculate nucleus (dLGN) of

42 etrogradely with biotinylated dextran amine (BDA) injected into the visual cortex.

43 Gross biocytin/biotinylated dextran amine (BDA) injections into the SG or extrastriate cortex label

44 s, at which time biotinylated dextran amine (BDA) injections were made into the SI.

45 terograde tracer biotinylated dextran amine (BDA) into 126 sites centered about the right lower extre

46 Injections of biotinylated dextran amine (BDA) into Av labeled both afferent terminals and neurons

47 ng injections of biotinylated dextran amine (BDA) into cortical area 17, two types of corticothalamic

48 natomical tracer biotinylated dextran amine (BDA) into different tonotopic regions of the LSO of albi

49 de injections of biotinylated dextran amine (BDA) into layer 3 of macaque prefrontal area 9 and exami

50 terograde tracer biotinylated dextran amine (BDA) into layers 2-5 of each area, labelled axonal varic

51 Injection of biotinylated dextran amine (BDA) into physiologically identified shoulder responsive

52 ll injections of biotinylated dextran amine (BDA) into SI barrel cortex.

53 We injected biotinylated dextran amine (BDA) into single vibrissal 'barrels' of primary somatose

54 Injections of biotinylated dextran amine (BDA) into the dorsal cochlear nucleus (DCN) of the rat l

55 terograde tracer biotinylated dextran amine (BDA) into the heterotopic cortex.

56 Injections of biotinylated dextran amine (BDA) into the InC anterogradely labeled axons that termi

57 ve axonal tracer biotinylated dextran amine (BDA) into the left nodose ganglion in rats.

58 terograde tracer biotinylated dextran amine (BDA) into the medial preoptic (MPO) produced dense label

59 cers biocytin or biotinylated dextran amine (BDA) into the MGV labeled thalamocortical afferent patch

60 Injection of biotinylated dextran amine (BDA) into the PVH produced clusters of BDA-positive nerv

61 nt injections of biotinylated dextran amine (BDA) into the right motor cortex.

62 ced by injecting biotinylated dextran amine (BDA) into the sensorimotor cortex of one hemisphere eith

63 xidase (HRP) and biotinylated dextran amine (BDA) into the utricular macula; and 2) to investigate th

64 acing, either by biotinylated dextran amine (BDA) labeled with immunogold-silver or by degeneration a

65 ade transport of biotinylated dextran amine (BDA) or Phaselous leucoagglutinin placed in the superior

66 dase labeling of biotinylated dextran amine (BDA) or Phaseolus vulgaris-leucoagglutinin (PHA-L) from

67 Injections of biotinylated dextran amine (BDA) that included this caudomedial riMLF region anterog

68 iculus (SC) with biotinylated dextran amine (BDA) to backfill retinal axons, which also project to th

69 ade transport of biotinylated dextran amine (BDA) to identify dendrites of forward-projecting neurons

70 terograde tracer biotinylated dextran amine (BDA) to investigate intra-SCN connectivity and the neura

71 of anterogradely biotinylated dextran amine (BDA) tracing combined with retrogradely horseradish pero

72 n (WGA-HRP) with biotinylated dextran amine (BDA) transport.

73 injection of 10% biotinylated dextran amine (BDA) unilaterally into the Vsup anterogradely labeled ax

74 Biotinylated dextran amine (BDA) was initially iontophoresed into the dorsal part of

75 terograde tracer biotinylated dextran amine (BDA) was injected into the lumbosacral dorsal gray commi

76 Biotinylated dextran amine (BDA) was injected into the right sensorimotor cortex to

77 erograde tracer, biotinylated dextran amine (BDA) was injected into the rvlm and a retrograde tracer,

78 Biotinylated dextran amine (BDA) was injected into the somato-motor cortex to trace

79 terograde tracer biotinylated dextran amine (BDA) was injected into the ventrolateral PAG, and labele

80 erograde tracer, biotinylated dextran amine (BDA) was iontophoresed bilaterally into the caudal NTS t

81 Thus, biotinylated dextran amine (BDA) was iontophoretically injected into the ventral med

82 Tracing with biotinylated dextran amine (BDA) was used to assess intra-SI projections of adult ra

83 Biotinylated dextran amine (BDA) was used to label the corticostriatal projection fr

84 trograde tracer, biotinylated dextran amine (BDA) were injected into localized regions of the caudal

85 al injections of biotinylated dextran amine (BDA) were made into different CNIC regions.

86 in diameter) of biotinylated dextran amine (BDA) were placed in different locations of the primary m

87 techniques with biotinylated dextran amine (BDA) were used to examine the terminal field structure a

88 ade transport of biotinylated dextran amine (BDA) with immunogold-silver labeling of a D2 receptor an

89 the second with biotinylated dextran amine (BDA) with Vector slate grey and 3,3'-diaminobenzidine te

90 traced by using biotinylated dextran amine (BDA), and many BDA-ir boutons were found to contain gala

91 ade tracing with biotinylated dextran amine (BDA), and retrograde tracing with fluorescent pseudorabi

92 as achieved with biotinylated dextran amine (BDA), and the MOR was detected by using antipeptide MOR

93 oxidase (HRP) or biotinylated dextran amine (BDA), but large percentages of efferent neurons were fou

94 r the other with biotinylated dextran amine (BDA)-3000 molecular weight.

95 terograde tracer biotinylated dextran amine (BDA).

96 terograde tracer biotinylated dextran amine (BDA).

97 unit B (CTB) and biotinylated dextran amine (BDA).

98 nce of mini-ruby biotinylated dextran amine (BDA).

99 inin (PHA-L) and biotinylated dextran amine (BDA).

100 han tracing with biotinylated dextran amine (BDA).

101 the widely used biotinylated dextran amine (BDA).

102 terograde tracer biotinylated dextran amine (BDA).

103 Using biotinylated dextran amine (BDA)/biocytin injections, we describe the cortical proje

104 anterogradely by biotinylated dextran amine (BDA)10k injection into the contralateral motor or primar

105 nsported form of biotinylated dextran amine (BDA; 10,000 molecular weight) in the pigeon dorsal palli

106 Then, biotinylated dextran amine (BDA; 10,000 MW) was injected in the center of the PMv di

107 We deposited biotinylated dextran amine (BDA; 3,000 MW), a retrograde tracer, unilaterally into t

108 ade transport of biotinylated dextran-amine (BDA) delivered to incisions made across the nerve fiber

109 ns of the tracer biotinylated dextran-amine (BDA) into the ventrolateral white matter at T9.

110 s of biocytin or biotinylated dextran-amine (BDA) were made into the guinea pig trigeminal ganglion,

111 inylated tracers biocytin and dextran-amine (BDA) with glutamate immunohistochemistry.

112 I, biocytin, and biotinylated dextrin amine (BDA).

113 of anterograde (biotinylated dextran amine; BDA) and retrograde (cholera toxin B) tracers where RTN

114 r injections of biotinylated dextran amines (BDA) in seven auditory cortical areas.

115 nin (PHA-L) and biotinylated dextran amines (BDA)] tracers were employed to study the putative connec

116 lliei, by using biotinylated dextran amines (BDA, 3,000 MW).

117 Blocker displacement amplification (BDA) method can stably and effectively detect and enrich

118 d on the Blocker Displacement Amplification (BDA) technology, is capable of detecting BRAF V600 mutat

119 To apply Bayesian decision analysis (BDA) to cancer therapeutics to choose an alpha and sampl

120 rved in all cases examined, for both AAV and BDA.

121 Terminal labeling after biocytin and BDA injections into the ganglion was found to be most de

122 ely normal patterns of both CO densities and BDA-labelled intracortical projections.

123 Both DiI and BDA revealed primary olfactory projections to the olfact

124 SII contained at least two row-like FR- and BDA-labeled strips that formed mirror image representati

125 ate parts of the same SI barrel row, FR- and BDA-labeled terminals tended to merge into a single stri

126 ntary interdigitating patches of WGA-HRP and BDA labeling were found primarily in transitional border

127 emical reaction for visualization of HRP and BDA, the BDA-labeled fibers and terminals were seen dist

128 njected into the dentate gyrus and PHA-L and BDA were injected into the entorhinal cortex to determin

129 a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivi

130 rred to as biosynthetic domain architecture (BDA).

131 oplastic graft material in bone defect area (BDA) reduction of 2-wall defects.

132 method to assess biliary duct number, area (BDA), portal vein area, and total area of each portal fi

133 Here, we present allele-specific BDA (As-BDA), a method combining BDA with allele-specific TaqMan

134 Further, As-BDA could detect up to four mutations with low to 0.1% V

135 The median error of As-BDA in VAF determination is approximately 9.1%.

136 Hence, we have shown that As-BDA can achieve simultaneous enrichment and identificati

137 We demonstrated that As-BDA could detect mutations down to 0.01% VAF.

138 Comparison experiments using As-BDA and droplet digital PCR on peripheral blood mononucl

139 Comparison experiments using As-BDA and droplet digital PCR on peripheral blood mononucl

140 l cortical regions, produced varicose axonal BDA labeling in a patch-like distribution in the dorsome

141 Approximately 64% of synapses between BDA-labeled boutons and HRP-labeled motoneurons were asy

142 ctylammonium (OCA), and 1,4-butyldiammonium (BDA) cations.

143 present in 19% of the dendrites contacted by BDA-labeled terminals but were present rarely in both th

144 area 7a), 94.2% of the synapses furnished by BDA-labeled intrinsic collaterals of supragranular pyram

145 that were in register with those labeled by BDA injections into the MGV.

146 One hundred sixty-eight appositions made by BDA-labeled terminals on HRP-labeled motoneurons were se

147 rm nucleus (Uva), which was substantiated by BDA injections into Uva that labeled terminals in Av.

148 BDA and Cl-BDA formation was also observed during the chlorination

149 ho to the hydroxy group inhibited BDA and Cl-BDA formation, but the chlorination of cresols and 2,3-d

150 nated analogue, chloro-2-butene-1,4-dial (Cl-BDA), after the chlorination of phenol, para- and ortho-

151 Combined BDA-366 and RAD001 treatment exhibits strong synergy aga

152 le-specific BDA (As-BDA), a method combining BDA with allele-specific TaqMan (As-TaqMan) probes for e

153 opy showed that in these patch compartments, BDA labeling was present exclusively in axons and termin

154 We computed BDA-optimal parameters for the 23 most common cancer sit

155 ng NCI and Alliance data, and then computing BDA-optimal type 1 error rates and sample sizes for onco

156 ents, and high prevalence, the corresponding BDA-optimal error rates were much lower, in some cases e

157 the lateral CST ipsilateral to the cortical BDA injection, and 87.9 +/- 1.0% of total CST axons proj

158 y at all cervical levels, particularly dense BDA labeling was observed in laminae VIII and IX ipsilat

159 ly by injecting a mixture of biotin dextran (BDA) with 3H-amino acids into the affected eye immediate

160 ract-tracing with biotinylated dextranamine (BDA) and fluorescence immunohistochemistry visualized wi

161 dely labeled with biotinylated dextranamine (BDA).

162 ta-unsaturated dialdehyde 2-butene-1,4-dial (BDA) and its chlorinated analogue, chloro-2-butene-1,4-d

163 -dimethylphenol yielded methyl- and dimethyl-BDA species.

164 Dual BDA and ZAP-70 positivity had a median OS of 84 months (

165 Under light microscopical examination, BDA-labeled terminals were observed closely apposing the

166 urons showed that after MSC treatment, fewer BDA-positive fibers crossed the CC and extended into the

167 However, BDA did not correlate with Bax protein levels: BDA posit

168 However, BDA reduction was statistically greater in group 2 (48.8

169 agglutinin-horseradish peroxidase (WGA-HRP), BDA, or a fluorescent tracer, iontophoretically injected

170 In BDA-labeled tissue prepared for electron microscopic ana

171 with PD reduction, CAL gain, and changes in BDA in both groups, which was statistically significant

172 sitions ortho to the hydroxy group inhibited BDA and Cl-BDA formation, but the chlorination of cresol

173 r, and the highly specific calpain inhibitor BDA-410 restored normal synaptic function both in hippoc

174 alamocortical terminals labeled by injecting BDA into the ventroposterolateral nucleus (VPL) were obs

175 ormed double-labeling experiments, injecting BDA in the CRNs and subunit B of the cholera toxin or Fl

176 At 20-23 d after injury, BDA-labeled CST axons did not extend past the lesion exc

177 Additionally, Ir-BDA/Ir-CDA can image NO in brain cancer cell models, neu

178 Ir-CDA and Ir-BDA utilize iridium (III) as the central ion and incorpo

179 ridium phosphorescence probes, Ir-CDA and Ir-BDA, have been designed to visualize the gasotransmitter

180 Some double-labeled BDA/VGAT varicosities were seen apposed to small somata

181 copy for the presence of peroxidase-labeled, BDA-containing vagal afferents and immunogold MOR labeli

182 A did not correlate with Bax protein levels: BDA positive and negative cases had high and low baselin

183 g biotinylated dextran amine (BDA), and many BDA-ir boutons were found to contain galanin immunoreact

184 an amine (BDA) in the area of the rVRG, many BDA-labeled terminals in the ventral horn of cervical sp

185 Under electron microscopy BDA-labeled boutons containing clear, spherical synaptic

186 By electron microscopy, BDA- or PHA-L-labeled axon terminals originating from th

187 In both models, BDA- and NPY-colabeled fibers were limited mainly to the

188 trastructural examination revealed that most BDA-labeled terminals contained clear spherical vesicles

189 t regions which is 2-fold longer than normal BDA in the experiments.

190 Of 173 observed BDA-labeled vagal afferent axon terminals, 33% contained

191 respectively, a higher density (P < 0.05) of BDA(+) fibers was found in thoracic dorsal gray matter o

192 Within RTN, 51% of BDA-labelled axonal varicosities contained detectable le

193 Approximately 57% and 62% of BDA-labeled terminals originating from the medial (n=150

194 We found that daily administration of BDA-410, a calpain-1 inhibitor, strikingly ameliorated m

195 To assess the functional association of BDA injection sites in the ITN, the known topographical

196 mine (BDA) into the PVH produced clusters of BDA-positive nerve terminals within the ipsilateral RVLM

197 ions were processed for the demonstration of BDA or CO.

198 the ipsilateral XII, the highest density of BDA labeling was found in the dorsal compartment and the

199 ent whisker barrel rows, the distribution of BDA- and FR-labeled terminals in the neostriatum followe

200 r tangential sectioning, the distribution of BDA-labeled cell bodies and terminal boutons was documen

201 ions of the retrogradely transported form of BDA (3,000 molecular weight) in the pigeon dorsal thalam

202 s, labelled by an in vivo focal injection of BDA, were examined using correlated light and electron m

203 Precise iontophoretic injections of BDA and CTB in the mSCN and vSCN were used to identify e

204 abeled anterogradely following injections of BDA in the VCN.

205 Discrete injections of BDA into auditory cortex labeled bands of neurons in the

206 Small injections of BDA were made in the anterior cingulate, medial agranula

207 Finally, after injections of BDA, a small number of retrogradely labeled pyramidal ne

208 ere processed for peroxidase localization of BDA and gold-silver labeling of tyrosine hydroxylase (TH

209 Instead, the majority of BDA-labeled fibers in the rRPa were orexin positive.

210 Measurement of BDA-labeled terminals in the spinal cord gray matter rev

211 Discrete microinjections of BDA were placed into either the medial or lateral aspect

212 mentary patterns of anterograde migration of BDA and 3H label in the cut and intact retinal axons, re

213 after injury, however, a novel population of BDA-labeled CST axons could be seen extending from the g

214 The proportions of BDA-labeled axon terminals forming asymmetric synapses w

215 Serial section reconstruction of BDA-labeled corticothalamic neurons in VIa revealed pyra

216 that AAV has actions equivalent to those of BDA as an anterograde tracer and is suitable for analysi

217 y of neurons infected compared with those of BDA.

218 Anterograde transport of BDA from injections into the PBN and KF nuclei of rabbit

219 Maximum yields of BDA were observed when chlorine was present in large exc

220 Among the biliary QT, only BDA correlated with the renal QT (P < 0.01).

221 Injections of the tracers PHA-L or BDA into these auditory-responsive posterior thalamic nu

222 In contrast to the other pathways, BDA-labeled ascending sensory axons did extend into and

223 cal attachment level (CAL), and radiographic BDA were done at the baseline and 6-month postoperative

224 Specifically in lactating rats, BDA-and NPY-colabeled axonal swellings were in close app

225 The PPNd also contained retrogradely BDA-labeled neurons which were contacted by anterogradel

226 synthesized from tartrates employing Ley's "BDA" and "Dispoke" methodologies as the key step.

227 Finally, we combined selective BDA labeling of IT-type or PT-type terminals with immuno

228 Although some BDA-labeled axons with varicosities were found bilateral

229 Here, we present allele-specific BDA (As-BDA), a method combining BDA with allele-specifi

230 treatment (16 vs 156 months, P = .029) than BDA negative cases.

231 tron microscopic observations indicated that BDA-labeled boutons form asymmetric synapses mainly on 0

232 The BDA assay measures the intrinsic ubiquitin/proteasome ac

233 The BDA-labeled axons in the ventral column were on the same

234 The BDA-labeled fibers were seen descended along Probst' tra

235 The BDA-labeled neurons in deep layer V and layer VI of the

236 action for visualization of HRP and BDA, the BDA-labeled fibers and terminals were seen distributing

237 Approximately 19% of the BDA and PHA-L axon terminals examined originating from t

238 ach target region, a large percentage of the BDA-ir varicosities was VGLUT2-ir (41-83%).

239 Thirty percent of the BDA-labeled terminals formed asymmetric excitatory synap

240 existing treatments, and low prevalence, the BDA-optimal type 1 error rates were much higher than the

241 re more dense on the side ipsilateral to the BDA deposit, and both A7 and locus coeruleus neurons rec

242 processed sequentially for WGA-HRP, and then BDA immunohistochemistry using two different chromogens.

243 Many of these BDA-labeled terminals formed asymmetric, excitatory-type

244 Two hundred and sixty-five of these BDA-labeled terminals were examined at the ultrastructur

245 Within the A lamina of the dLGN, this BDA labeling allowed us to distinguish Y retinogeniculat

246 rizing core biosynthetic machineries through BDA, we identified key BDAs of modular BGCs in diverse e

247 he midbrain by injecting the neuronal tracer BDA into different branches of the lateral line nerve an

248 horetic injection of the anterograde tracers BDA, neurobiotin and PHA-L in the host.

249 Although traditional BDA tracing cannot reliably visualize regenerating ngr1(

250 One hundred and twelve BDA-labeled axon terminals were observed synapsing with

251 Adult female grass rats received unilateral BDA injections directed at the SCN or vSPVZ and their br

252 racterize the LRN projection to the CN using BDA injections.

253 xperiments on adjacent tissue sections using BDA Sanger, immunohistochemistry (IHC), digital droplet

254 ompartment of the ventral compartment, where BDA labeling formed a dense, patchy distribution.

255 r accounts using different tracers, but with BDA they are labeled more fully.

256 serotype 1) was systematically compared with BDA as an anterograde tracer by injecting both tracers i

257 GFP is 10 times more efficient compared with BDA.

258 eled with BDA, sometimes doubly labeled with BDA and (3)H-leucine, were in close apposition with dend

259 Axons and swellings labeled with BDA and olivocochlear neurons labeled with CTB were immu

260 ntrolateral medullary efferents labeled with BDA were apposed to thoracic reticulospinal neurons labe

261 We found that swellings labeled with BDA, sometimes doubly labeled with BDA and (3)H-leucine,

262 Double labeling with BDA and (3)H-leucine signifies that the label was antero

263 ent of contralesional rewiring measured with BDA and PRV tracing was related to sensorimotor dysfunct

264 Patients with BDA positive cells had a shorter median overall survival

265 Anterograde tracing with BDA demonstrated that RVLM and MCVA are interconnected.